Neuro-Oncology News

Higher tissue 2-hydroxyglutarate concentration appeared to increase risk for preoperative seizures in isocitrate dehydrogenase 1/2 mutant tumors, according to study results published in Neurology.

The FDA granted breakthrough device designation to Alpha DaRT for treatment of recurrent glioblastoma multiforme.

Brain and central nervous system tumors are the second most common malignancy among children and the most prevalent form of solid tumor, according to American Cancer Society data.

People with MS had lower overall and cancer-specific survival soon after colorectal cancer diagnosis compared with those without MS, according to results of a retrospective matched cohort study published in Neurology.

An expert panel has developed recommendations on best practices for managing clinically relevant immune-related adverse events associated with immune checkpoint inhibitor treatment.

The FDA granted orphan drug designation to LP-184 for the treatment of glioblastoma multiforme and other malignant gliomas.

Vascular endothelial growth factor and immune checkpoint inhibitors may help prevent brain metastases among patients with solid tumors, according to results from a systematic review and meta-analysis published in Neurology.

Neuro-oncologists must grapple daily with precarious brain tumors that are often masked by common symptoms such as a headache or seizure.

The FDA approved belzutifan for treatment of cancers associated with von Hippel-Lindau disease.

In this episode, Priya U. Kumthekar, MD, discusses her entry into the field of neuro-oncology, her insight into translational medicine and its applications outside of medicine, and more.